Clinical trials in Nantes – page 25

951 clinical trials in Nantes, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in FranceEssaisCliniques.fr

Nantes at a glance

951

clinical trials

Research sites2

Quick filters

951 trials in Nantes

Open in trial search

B-cell type acute leukaemia

Recruiting

Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Registered drugNo placebo

Study on the Safety and Effectiveness of AZD0486 and Tocilizumab for Adolescents and Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Registered drugNo placebo

France

Participants:0–17 years · 18–64 years · 65+ years
Substances:Tocilizumab
Sponsor:AstraZeneca AB

Contact Research Centre

Plasma cell myeloma

Recruiting

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel or Stem Cell Transplant for Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel or Stem Cell Transplant for Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Emn Trial Office S.r.l. Impresa Sociale

Contact Research Centre

Neoplasm

Recruiting

Study of Patritumab Deruxtecan for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo

Study of Patritumab Deruxtecan for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Patritumab Deruxtecan
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Plasma cell myeloma refractory

Recruiting

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Pfizer Inc.

Contact Research Centre

Peritoneal sarcoma+5

Recruiting

Study on Adjusting Chemotherapy with Carboplatin and Paclitaxel for Patients with Poor Prognostic Ovarian Cancer

Registered drugNo placebo

Study on Adjusting Chemotherapy with Carboplatin and Paclitaxel for Patients with Poor Prognostic Ovarian Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Arcagy Gineco

Contact Research Centre

Hormone receptor positive breast cancer

Recruiting

Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

Registered drugNo placebo

Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Chronic lymphocytic leukaemia+1

Recruiting

Study on Lisaftoclax and Acalabrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo

Study on Lisaftoclax and Acalabrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Acalabrutinib
Sponsor:Ascentage Pharma Group Inc.

Contact Research Centre

Plasma cell myeloma

Recruiting

Study on the Safety and Effectiveness of AZD0305 Alone and with Other Cancer Drugs for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Study on the Safety and Effectiveness of AZD0305 Alone and with Other Cancer Drugs for Adults with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Azd0305
Sponsor:AstraZeneca AB

Contact Research Centre

Penile cancer

Recruiting

Study on the Effects of Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin for Patients with Squamous Cell Carcinoma of the Penis and Lymph Node Metastasis

Registered drugNo placebo

Study on the Effects of Chemotherapy with Paclitaxel, Ifosfamide, and Cisplatin for Patients with Squamous Cell Carcinoma of the Penis and Lymph Node Metastasis

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Aprepitant
Sponsor:Unicancer

Contact Research Centre

Coronary artery disease

Recruiting

Study on Dual Antiplatelet Therapy Duration for Patients with Chronic Coronary Artery Blockage Using Clopidogrel and D,L-Lysine Acetylsalicylate

Registered drugNo placebo

Study on Dual Antiplatelet Therapy Duration for Patients with Chronic Coronary Artery Blockage Using Clopidogrel and D,L-Lysine Acetylsalicylate

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Clopidogrel
Sponsor:Centre Hospitalier Regional De Marseille

Contact Research Centre

Nephroblastoma

Recruiting

Study Comparing Vincristine, Actinomycin-D, and Doxorubicin with Vincristine, Carboplatin, and Etoposide for Stage IV Childhood Kidney Cancer Patients

Registered drugNo placebo

Study Comparing Vincristine, Actinomycin-D, and Doxorubicin with Vincristine, Carboplatin, and Etoposide for Stage IV Childhood Kidney Cancer Patients

Registered drugNo placebo

France

Participants:0–17 years
Substances:Carboplatin
Sponsor:GPOH gGmbH

Contact Research Centre

Atrial fibrillation+1

Recruiting

Study on the Safety and Effectiveness of Apixaban and Warfarin for Patients with End-Stage Renal Disease on Peritoneal Dialysis and Atrial Fibrillation

Registered drugNo placebo

Study on the Safety and Effectiveness of Apixaban and Warfarin for Patients with End-Stage Renal Disease on Peritoneal Dialysis and Atrial Fibrillation

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Centre Hospitalier Universitaire De Caen Normandie

Contact Research Centre

Other cities in France

The busiest research cities in the country

All 380 cities in France

Clinical research in Nantes

What the registry says about research in the country

01 Oncology and Hematology

Advanced research focusing on multiple myeloma, leukemia, and various lymphomas. Studies are evaluating novel treatment combinations and therapeutic approaches for blood cancers.

Multiple Myeloma Treatments
Lymphoma Therapies
Leukemia Management

Innovative trials exploring combinations of targeted therapies and immunotherapies to improve patient outcomes.

02 Infectious Diseases

Comprehensive studies on preventive measures against viral infections, including trials for vaccines targeting CMV, yellow fever, and mpox.

Vaccine Development
Viral Prevention
Immunization Studies

Focus on developing and evaluating new vaccine formulations and delivery methods.

03 Autoimmune Conditions

Research investigating treatments for inflammatory bowel diseases and multiple sclerosis, including innovative approaches like fecal microbiota transplantation.

Crohn's Disease
Ulcerative Colitis
MS Treatment Strategies

Exploring novel therapeutic options and treatment de-escalation strategies.

04 Critical Care Medicine

Studies addressing postoperative care and management of severe conditions in intensive care settings, including burns and immune suppression.

Post-Surgery Care
Burn Treatment
ICU Interventions

Evaluating new approaches to improve patient comfort and outcomes in critical care.

Back to France All countries